budipine

04/22/1996 - "Budipine is a novel antiparkinsonian drug which is particularly beneficial in the treatment of parkinsonian tremor. "
03/01/1999 - "Tremor occurrence improved in the budipine group (n = 7) from 24.7 +/- 15.5% to 14.8 +/- 14.5% (p < 0.05). "
01/01/1999 - "Tremor occurrence was improved in the budipine group (n = 7) from 24.7 +/- 15.5% to 14.8 +/- 14.5% (p < 0.05). "
01/01/1999 - "In clinical trials budipine reduced tremor, akinesia and rigidity. "
06/01/1995 - "We conclude that budipine is an effective and well-tolerated tremorlytic drug and that the method of long-term EMG recording is suitable for tremor quantification in clinical studies."

05/01/2002 - "Previous studies have demonstrated the therapeutic efficacy of budipine on motor symptoms in insufficiently treated patients with Parkinson disease. "
06/01/1987 - "Owing to its long half-life (31 h) with little plasma level fluctuations, budipine appears to be an effective agent in the treatment of Parkinson's disease."
08/01/2005 - "Previous studies demonstrated the efficacy of budipine on motor symptoms of treated patients with Parkinson's disease (PD) with rating scales. "
08/01/2005 - "Efficacy of budipine and placebo in untreated patients with Parkinson's disease."
04/01/2000 - "An open, prospective, long-term study of 2532 patients with Parkinson's disease (Study BY701/01A) confirmed the favorable safety and tolerability profiles of budipine."

01/01/1986 - "The t-butyl analogue in this class of substances, budipine, is a novel therapeutic agent for Parkinsonism whose mechanism has not yet been fully clarified. "
01/01/1988 - "Our observations show a new aspect of the MPP+ mode of action, in which deprenyl in mice has a partially protective effect against MPP+. Furthermore budipine, a therapeutic agent for Parkinsonism, is also able to partially prevent MPP+ toxicity. "
05/06/2002 - "Over the last six years, eight new substances for the treatment of idiopathic parkinsonism (IP) have been approved for use: four oral and one parenteral dopamine agonist (apomorphine), two COMT-inhibitors and budipine. "

06/01/1987 - "The additional administration of budipine (daily dose 60 mg) was excellently tolerated by 14 patients, while 2 patients left the study because of mental confusion at an early stage of the trial. "

06/01/2003 - "In the first part of the study possible additional antioxidative effects of various N-methyl-D-aspartate (NMDA)-receptor antagonists, some of which are used in the treatment of Parkinson's or Alzheimer's disease or as narcotic (dizocilpine, ketamine, budipine, memantine, amantadine, AP-5) were investigated in vitro in comparison to the respective agonists (NMDA, glutamate, aspartate, glycine) and the putative antioxidative amino acid taurine. "